NCT05994131View on ClinicalTrials.gov

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

NSCLC

Interventions

DRUG

IN10018

orally taken once daily

DRUG

Furmonertinib

orally taken once daily

Trial Locations (1)

Unknown

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY